Pegasys Market Position Secure, Roche Says; Dismisses PEG-Intron Data
Executive Summary
Roche expects to have firmly established its leadership position in the hepatitis C market with Pegasys by the time Schering-Plough publishes the results from its ongoing head-to-head study versus PEG-Intron
You may also be interested in...
Pegasys Gets HIV Co-Infection Claim; Market Expansion Moves Forward
Roche is looking to a new chronic hepatitis C indication for Pegasys in patients co-infected with HIV to expand its hepatitis market penetration
Pegasys Gets HIV Co-Infection Claim; Market Expansion Moves Forward
Roche is looking to a new chronic hepatitis C indication for Pegasys in patients co-infected with HIV to expand its hepatitis market penetration
Roche, Schering Look To Grow Hepatitis Market; Pegasys Share Surges
Roche and Schering-Plough are attempting to drive sales of their hepatitis products by growing the market while increasing share